agilon health, inc.

agilon health, inc.(AGL)の株式分析

$87.400

+1.530 (+1.75%)終値時点

Loading chart…
高値
87.400
始値
84.080
出来高加重平均価格
86.29
出来高
145.32K
時価総額
2.71B
安値
84.080
売買代金
12.54M
EV/EBITDA(TTM)
12.48

agilon health, inc. is a healthcare company. The Company operates a Medicare-centric, capitated line of business. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing monthly payments to manage the total healthcare needs of its physician partners attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform supports the transition to a Total Care Model with technology, people, process and capital.

www.agilonhealth.com

AI分析 of agilon health, inc. (AGL)

買い

Agilon Health Inc. is a good buy right now due to its recent strong earnings performance, with Q2 2026 revenue of $1.49 billion exceeding expectations and adjusted EPS of $2.15 far surpassing the estimate of $0.27. Additionally, the stock has a significant upside potential with an analyst price target of $125, representing a potential increase of 51.5% from the current price of $82.39. However, a key risk is the negative net income reported in recent quarters, with a net income of $17.96 million in Q2 2026, which indicates ongoing challenges in profitability.

バリュエーション指標

agilon health, inc.(AGL)の現在の予想PERは178.57で、5年平均は26.95です。

予想PER

適正
5年平均 P/E
26.95
現在のP/E
178.57
割高
320.00
割安
-266.11

予想EV/EBITDA

適正
5年平均 EV/EBITDA
146.56
現在のEV/EBITDA
12.48
割高
588.29
割安
-295.17

予想PSR

適正
5年平均 P/S
1.17
現在のP/S
0.23
割高
2.40
割安
-0.06

Alphio AI による AGL の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%AGL

$3.37

シナリオ価格

基

基本

基本 · 50%AGL

$3.18

シナリオ価格

弱

弱気

弱気 · 25%AGL

$2.51

シナリオ価格

AGL を保有するクジラ

I

IOOF Investment Management Limited

+ を保有AGL

-1.71%

3か月リターン

D

Durable Capital Partners, LP

+ を保有AGL

-6.36%

3か月リターン

R

Rock Springs Capital Management LP

+ を保有AGL

-11.63%

3か月リターン

イベントタイムライン

2026-09-30 (ET)

09:30:00

Agilon Health Expands Partnership with The Jackson Clinic

2026-09-23 (ET)

09:30:00

Agilon Health Expands Partnership with Springfield Clinic

2026-09-10 (ET)

09:30:00

Agilon Health Expands Partnership with Family Practice Center

2026-08-05 (ET)

17:00:00

Sees Q3 Adjusted EBITDA at -$5M

17:00:00

agilon health Q2 Revenue $1.49B, Exceeds Expectations

ニュース

AGL のよくある質問 — Alphio AI が回答

agilon health, inc. is a healthcare company. The Company operates a Medicare-centric, capitated line of business. Through its combination of the agilon platform, a long-term partnership model with existing physician groups and a growing network of like-minded physicians, it offers healthcare for seniors across communities throughout the United States. Its model operates by primarily forming risk-bearing entities (RBEs) within local geographies, that enter into arrangements with payors providing monthly payments to manage the total healthcare needs of its physician partners attributed patients (or global capitation arrangements). It focuses on community-based physician groups and is built around three key elements: agilon’s platform, agilon’s long-term physician partnership approach, and agilon’s network. The agilon platform supports the transition to a Total Care Model with technology, people, process and capital. It operates in the Healthcare sector (SERVICES-MISC HEALTH & ALLIED SERVICES, NEC industry).

Agilon Health Inc. is a good buy right now due to its recent strong earnings performance, with Q2 2026 revenue of $1.49 billion exceeding expectations and adjusted EPS of $2.15 far surpassing the estimate of $0.27. Additionally, the stock has a significant upside potential with an analyst price target of $125, representing a potential increase of 51.5% from the current price of $82.39. However, a key risk is the negative net income reported in recent quarters, with a net income of $17.96 million in Q2 2026, which indicates ongoing challenges in profitability.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める